Side Effects
Sermorelin has a well-established safety profile from its years as an FDA-approved medication. The following adverse effects have been reported in clinical trials and post-marketing experience:
Common (typically mild and self-limiting):
- Injection site reactions: pain, redness, swelling, or itching at the injection site, the most frequently reported adverse event in clinical studies
- Facial flushing: a brief warm, red sensation in the face and neck, typically resolving within 5 to 20 minutes post-injection
- Headache: mild headache reported in a subset of patients, most commonly during the first 1 to 2 weeks of therapy
- Dizziness or lightheadedness, particularly with initial doses
Less common:
- Nausea
- Drowsiness or restlessness
- Transient urticaria (hives)
- Mild water retention
- Difficulty swallowing (reported rarely with the injectable form)
- Altered taste perception
Rare but clinically significant:
- Hypersensitivity reactions: severe allergic symptoms including facial swelling, difficulty breathing, or anaphylaxis. These require immediate medical attention
- Antibody formation: a large proportion of pediatric patients in clinical trials developed anti-sermorelin antibodies at least once during treatment, though antibody presence at one assessment often became negative by the next and did not appear to affect growth outcomes in most cases
Precautions and contraindications:
- Active malignancy (GH and IGF-1 may promote growth of existing tumors)
- Hypothyroidism should be corrected before initiating therapy, as low thyroid function impairs GH response
- Concomitant glucocorticoid therapy may attenuate sermorelin's effects
- Obese patients may have blunted GH responses to sermorelin